OR-GUROBI-OPTIMIZATION
6.12.2022 15:02:17 CET | Business Wire | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology and creator of the world’s fastest mathematical optimization solver, recently announced the rebranding of its support team as “Gurobi Experts – Technical Advisory and Support Team.” This team of 15+ PhD-level optimization specialists is passionate about helping customers succeed with optimization and can provide comprehensive guidance on Gurobi products and mathematical optimization.
Matthias Miltenberger, Optimization Support Manager, explained that the reasoning behind the rebrand stemmed from some common misunderstandings about the word “support.”
“There’s this idea that ‘support’ means sitting in a call center all day with headphones on,” said Miltenberger. “Most people hear that word and think of experiences they’ve had calling up their phone or internet provider, which are often unpleasant experiences. And the assumption is that they’re not really talking to experts, so we definitely wanted to change that mindset.”
Indeed, the work of the Expert Team extends far beyond basic support. With over 150 years of optimization experience between them, the team works across three continents and uses their expert knowledge to provide a variety of services to customers around the world, including:
- Model troubleshooting: The Expert Team can help identify and troubleshoot unexpected problems, such as slow performance or code failure.
- Performance tuning: Rather than relying on a trial-and-error approach, the Expert Team often uses their expert knowledge to anticipate how the solver might react to certain parameter changes, which saves valuable time for customers.
- Outreach: On top of the virtual assistance they provide on a daily basis, they frequently attend conferences and events, where they teach attendees how to model problems, improve their models, and overcome many other common challenges. The team also shares their knowledge with Gurobi’s community forum, where customers can ask questions or share their own expertise.
“We’re people who care deeply about optimization and about helping our customers succeed,” explains Dr. Sonja Mars, who directs the team. “On any given day, you’ll see us digging deep into our customers’ complex installation questions, programming interfaces, performance tuning challenges, you name it.”
“In a nutshell, we help our customers get the most out of the Gurobi solver, which is a very complex and powerful product,” explained Miltenberger. “There’s the mathematical stuff, where you really need to understand what is happening inside the engine, but you also need to understand how to best use Gurobi on a variety of machine architectures.”
“Solving puzzles is what we do,” added Dr. Alison Cozad. “But what really excites me is working with customers. Understanding their problem, discussing with them, and then coming to a solution together—there’s nothing like it.”
Most customer communication with the Expert Team happens via email or a ticket system, which gives the team time to delve deep into an issue and find the best solution. However, the team is also available for video calls or screen-sharing sessions for issues that require more hands-on assistance. The team’s median first-reply time is just 27 minutes.
“We all love what we do,” explains Dr. Eli Towle. “Solving the most complex problems on the planet—where millions of trillions of possible solutions exist—in a short amount of time . . . that’s an exciting job.”
Gurobi customers appreciate the team’s personalized service, as well as the fact that the team can dedicate extra time to find solutions to complicated challenges. This is evidenced by their 98.5% positive customer satisfaction rating, as well as customer testimonials.
In addition to offering top-notch support, the Expert Team is constantly on the lookout for opportunities to innovate. Miltenberger recalls a case where one customer’s problem actually led to the development of a brand-new tool.
“For one particular customer with certain time constraints, I needed to come up with a new way of tuning their models. I saw this as an opportunity to create a new tool that makes it easier to complete all kinds of tuning requests. In the end, this solution turned into a software package called GRBlogtools, which the Expert Team now uses daily to analyze dozens or even hundreds of log files, to see if tweaking a parameter makes a difference in terms of performance.”
Learn more about how the Gurobi Expert Team uses its expertise to help users have the most successful optimization experience possible.
About Gurobi Optimization
With Gurobi’s decision intelligence technology, you can make optimal business decisions in seconds. From workforce scheduling, portfolio management, and marketing optimization, to supply chain design, and everything in between, Gurobi identifies your optimal solution, out of trillions of possibilities.
As the leader in decision intelligence, Gurobi delivers easy-to-integrate, full-featured software and best-in-class support, with an industry-leading 98% customer satisfaction rating.
Founded in 2008, Gurobi has operations across the Americas, Europe, and Asia. Over 2,500 global customers across 40+ industries run on Gurobi, including SAP, Air France, and the National Football League, as well as half of the Fortune 10 and 70% of top global tech companies. For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221206005457/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
